GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Oriental Bioengineering Inc (OTCPK:AOBI) » Definitions » Debt-to-Equity

AOBI (American Oriental Bioengineering) Debt-to-Equity : 0.33 (As of Sep. 2013)


View and export this data going back to 1991. Start your Free Trial

What is American Oriental Bioengineering Debt-to-Equity?

American Oriental Bioengineering's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2013 was $87.7 Mil. American Oriental Bioengineering's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2013 was $5.1 Mil. American Oriental Bioengineering's Total Stockholders Equity for the quarter that ended in Sep. 2013 was $283.7 Mil. American Oriental Bioengineering's debt to equity for the quarter that ended in Sep. 2013 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for American Oriental Bioengineering's Debt-to-Equity or its related term are showing as below:

AOBI's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

American Oriental Bioengineering Debt-to-Equity Historical Data

The historical data trend for American Oriental Bioengineering's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oriental Bioengineering Debt-to-Equity Chart

American Oriental Bioengineering Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.33 0.29 0.31 0.21

American Oriental Bioengineering Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.21 0.20 0.22 0.33

Competitive Comparison of American Oriental Bioengineering's Debt-to-Equity

For the Biotechnology subindustry, American Oriental Bioengineering's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Oriental Bioengineering's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Oriental Bioengineering's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where American Oriental Bioengineering's Debt-to-Equity falls into.



American Oriental Bioengineering Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

American Oriental Bioengineering's Debt to Equity Ratio for the fiscal year that ended in Dec. 2012 is calculated as

American Oriental Bioengineering's Debt to Equity Ratio for the quarter that ended in Sep. 2013 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Oriental Bioengineering  (OTCPK:AOBI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


American Oriental Bioengineering Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of American Oriental Bioengineering's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oriental Bioengineering Business Description

Traded in Other Exchanges
N/A
Address
1 Liangshuihe First Ave, Beijing E-Town, Economic and Technology Development Area, E-Town, Beijing, CHN, 100176
American Oriental Bioengineering Inc is a manufacturer of pharmaceutical and healthcare products. Its product line encompasses prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products.
Executives
Patti Cosimo J director AMERICAN ORIENTAL BIOENGINEERING, INC. 90 PARK AVENUE, 17TH FLOOR NEW YORK NY 10016

American Oriental Bioengineering Headlines

No Headlines